Generex Biotechnology Corporation CEO Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com
NEW YORK, May 9, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTC:GNBT) announced that their May 5th RetailInvestorConferences.com presentation is available for on-demand viewing.
LINK: www.retailinvestorconferences.com>Click the red "register/ watch event now" button.
Generex'spresentation will be available 24/7 for 90 days. Investors may download shareholder materials from the "virtual trade booth" for the next three weeks.
About Generex Biotechnology Corporation
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. The Company's buccal insulin spray product, Generex Oral-lyn™ is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T helper stimulation in immunotherapy. One of its platform technologies relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T helper cells and prevents the further growth of cancer cells. For more informat